Business Context and Reporting Period
This Form 8-K was filed by Nephros, Inc. on December 13, 2018. The report details a corporate governance event involving the appointment of a senior executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Andrew Astor, the Company's current Chief Financial Officer, was appointed to the additional position of Chief Operating Officer effective December 13, 2018.
- Compensation Adjustment: Mr. Astor's annual base salary was increased to $295,000, effective January 1, 2019.
- Equity Grant: Mr. Astor is expected to receive a grant of options to acquire 200,000 shares of common stock, vesting over a four-year period. The grant is subject to a future Board of Directors meeting.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. It notes that the terms of Mr. Astor's employment are governed by a Letter Agreement dated February 10, 2017, which was not amended in connection with this appointment.
Investor Verification Checklist
- Verify the formal grant of the 200,000 stock options at the next scheduled Board of Directors meeting.
- Confirm the effective date of the salary increase (January 1, 2019) in subsequent payroll or financial disclosures.
- Review the Company's 2018 Proxy Statement for the full terms of the existing Astor Employment Agreement.